 October 31, 2006
|
October 30, 2006
|
Progression-Free Survival Common For Pregnant Women
For pregnant HIV-infected women with access to highly active antiretroviral therapy (HAART), the medium-term postpartum prognosis is good, according to a report in the October 1st Journal of Acquired Immune Deficiency Syndromes.
|
|
|
October 27, 2006
|
Tyzeka Approved for Hepatitis B
The U.S. Food and Drug Administration (FDA) granted approval on Wednesday to Tyzeka? (telbivudine), a new treatment for chronic hepatitis B virus (HBV) infection.
|
|
|
October 26, 2006
|
Vaccine Series Safe In Children
Pneumococcal conjugate vaccine (PCV) followed by pneumococcal polysaccharide vaccine (PPV) appears to be safe and effective for certain HIV-infected children, researchers report in the October issue of the Pediatric Infectious Disease Journal.
|
|
|
October 24, 2006
|
Vulnerable HIV Patients Less Likely To Have Care
Members of minority groups, who are most at risk of contracting HIV infection and most likely to be in greatest need of service, are also the individuals who are least likely to be receiving medical care in the U.S., investigators report.
|
|
|
October 23, 2006
|
Enfuvirtide As Rescue Therapy
Findings from a small study suggest that the fusion inhibitor enfuvirtide (formerly T-20) is a useful therapeutic option for multi-class experienced HIV-infected patients.
|
|
|
October 20, 2006
|
New 300mg Reyataz Capsule Approved
Bristol-Myers Squibb announced today that it has received U.S. Food and Drug Administration (FDA) approval for a 300mg capsule version of its protease inhibitor Reyataz® (atazanavir). For HIV-positive people combining Reyataz with Norvir® (ritonavir), the 300mg Reyataz capsule can be used in place of the two 150mg capsules currently recommended when both drugs are taken together.
|
|
|
October 19, 2006
|
Anal HPV Infection Common in Women
Human papillomavirus (HPV) infection of the anus is more common than HPV infection of the cervix in HIV-positive women, according to new data reported last week at the 44th Annual Meeting of the Infectious Disease Society of America (IDSA) in Toronto.
|
|
|
| October 16, 2006
|
October 11, 2006
|
Bacteria Protein Prevents HIV Entry
The binding domain from Porphyromonas gingivalis gingipain prevents cell entry by HIV-1, according to a report in the September issue of Antimicrobial Agents and Chemotherapy.
|
|
|
October 10, 2006
|
New U.S. Treatment Guidelines
Norvir (ritonavir)-boosted Reyataz (atazanavir) and Lexiva (fosamprenavir) are comparable to Kaletra (lopinavir/ritonavir) as "preferred" protease inhibitor (PI) options for HIV-positive people starting therapy for the first time, according to new federal treatment guidelines issued by the U.S. Department of Health and Human Services (DHHS).
|
|
|
Tenofovir Prodrug Delays SHIV Infection
Nearly two-thirds of patients with HIV-associated dementia have actively changing cognitive status; the neurological status in the majority of these patients deteriorates but a significant minority improves, according to data presented here at the annual meeting of the American Neurological Association.
|
|
|
Course Of HIV Neurologic Disease Variable, Related To Platelet Count
Nearly two-thirds of patients with HIV-associated dementia have actively changing cognitive status; the neurological status in the majority of these patients deteriorates but a significant minority improves, according to data presented here at the annual meeting of the American Neurological Association.
|
|
|
October 06, 2006
|
First Test for Early HIV Infection
The U.S. Food and Drug Administration has announced the approval of Aptima®, a new assay that can be used to aid the detection of HIV in those who may be newly infected with the virus and cannot yet depend on the results of antibody testing.
|
|
|
October 05, 2006
|
Medecins Sans Frontieres Founder Wants Stronger WHO
The United Nations cannot take a backseat to private philanthropic foundations and needs more money to combat diseases like malaria and tuberculosis, the French candidate to lead the World Health Organisation (WHO) said on Thursday.
|
|
|
Boosted Atazanavir Of Mixed Benefit In Pediatric HIV
Switching to a once daily-regimen including ritonavir-boosted atazanavir appears helpful in some HIV-infected children, but has led to unexpected virological failure in others, according to French researchers
|
|
|
| October 03, 2006
|
October 02, 2006
|
ICAAC: Norvir-Boosted Lexiva vs. Reyataz
Early data from a study comparing Lexiva (fosamprenavir) to Reyataz (atazanavir), both combined with low-dose Norvir (ritonavir), suggest that both drugs have similar effectiveness.
|
|
|
|
